2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Computer - Aided Drug Design

• Publication date

  2016-06-06

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1573409912666160606150323PMID 27264509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

  2013cited by this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cited by this paper
• Molecular structure input on the web

  2010cited by this paper
• In silico QSAR studies of anilinoquinolines as EGFR inhibitors

  2010cited by this paper
• 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.

  2008cited by this paper
• Rational bases for the development of EGFR inhibitors for cancer treatment.

  2007cited by this paper
• The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.

  2007cited by this paper
• BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities

  2006cited by this paper
• ErbB receptors: new insights on mechanisms and biology.

  2006cited by this paper
• Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)*S

  2006cited by this paper
• Prediction oriented QSAR modelling of EGFR inhibition.

  2006cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• A comprehensive pathway map of epidermal growth factor receptor signaling

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• Pharmacological background of EGFR targeting.

  2004cited by this paper
• The Problem of Overfitting

  2004cited by this paper
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

  2003cited by this paper
• ErbB-targeted therapeutic approaches in human cancer.

  2003cited by this paper
• Assessing Model Fit by Cross-Validation

  2003cited by this paper
• The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

  2003cited by this paper
• 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

  2003cited by this paper
• Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.

  2002cited by this paper
• Tyrosine kinase inhibitors: From rational design to clinical trials

  2001cited by this paper
• Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

  2000cited by this paper

• 2-Amino Thiazole Derivatives as Prospective Aurora Kinase Inhibitors against Breast Cancer: QSAR, ADMET Prediction, Molecular Docking, and Molecular Dynamic Simulation Studies

  2023cites this paper
• In silico study combining QSAR, docking and molecular dynamics simulation on 2,4-disubstituted pyridopyrimidine derivatives

  2019cites this paper
• Combined QSAR model and chemical similarity search for novel HMG-CoA reductase inhibitors for coronary heart disease.

  2019cites this paper